Lipidomics Revealed Plasma Phospholipid Profile Differences between Deceased and Recovered COVID-19 Patients

Abstract

Thorough understanding of metabolic changes, including lipidome alteration, associated with the development of COVID-19 appears to be crucial, as new types of coronaviruses are still reported. In this study, we analyzed the differences in the plasma phospholipid profiles of the deceased COVID-19 patients, those who recovered and healthy people. Due to identified abnormalities in plasma phospholipid profiles, deceased patients were further divided into two subgroups (D1 and D2). Increased levels of phosphatidylethanolamines (PE), phosphatidylcholines (PC) and phosphatidylserines (PS) were found in the plasma of recovered patients and the majority of deceased patients (first subgroup D1) compared to the control group. However, abundances of all relevant PE, PC and PS species decreased dramatically in the plasma of the second subgroup (D2) of five deceased patients. These patients also had significantly decreased plasma COX-2 activity when compared to the control, in contrast to unchanged and increased COX-2 activity in the plasma of the other deceased patients and recovered patients, respectively. Moreover, these five deceased patients were characterized by abnormally low CRP levels and tremendous increase in LDH levels, which may be the result of other pathophysiological disorders, including disorders of the immune system, liver damage and haemolytic anemia. In addition, an observed trend to decrease the autoantibodies against oxidative modifications of low-density lipoprotein (oLAb) titer in all, especially in deceased patients, indicate systemic oxidative stress and altered immune system that may have prognostic value in COVID-19.

Chewing the fat: How lipidomics is changing our understanding of human health and disease in 2022

“…Since its outbreak in 2019, the world population has experienced a drastic change in lifestyle due to the unpredictable nature of the disease. Despite the explosive efforts by the scientific community, there remain many questions regarding its pathological mechanisms, treatment, and the clinical management of patients that research groups have attempted to address through lipidomics experiments 322–335 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 according to separation techniques, detectors, and RPLC columns used …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 using Scopus search terms “lipidomics” AND “clinic*” on 15 th December 2022 …”

“…Bibliometric analyses of clinical lipidomics publications in 2022 according to separation techniques, detectors, and RPLC columns used. 51,60,61,68,77,[155][156][157]166,[212][213][214][215][310][311][312][313][314][322][323][324][325][326][327][328][329][330][331][332][333][334][335] All legends are in order of largest to smallest percentage. *Note: All techniques that represent ≥1.0% of total publications have been reported.…”

“…Bibliometric analyses of clinical lipidomics publications in 2022 using Scopus search terms "lipidomics" AND "clinic*" on 15 th December 2022. 51,60,61,68,77,[155][156][157]166,[212][213][214][215][310][311][312][313][314][322][323][324][325][326][327][328][329][330][331][332][333][334][335] . *Note: All biological sample types with more than 1.0% of total publications have been reported individually with all remainder combined under "Other".…”